A First-in-Class Therapy Targeting Transcription-Replication Conflicts Drives Synthetic Lethality in Homologous Recombination Deficient Cancers
Lim, Y. C.; Lai, S. K.; Yang, R. H.; Chua, Y. K.; Patouret, R.; Manoj, V.; Soh, C.; Lebeau, B.; Cham, N.; Meng, W.; Tey, S. K.; Yeap, S. L.; Zhang, S.; Yong, J.; Ali, Z.; Mutwil, M.; Singh, P.; Fullwood, M.; Zhong, L.; Dong, X.; Chiba, S.; Koh, C. G.; Li, H. Y.
Show abstract
Hidden beneath the layer of tumor malignancy lies unchecked proliferation driven by hyperactive transcription, which fosters the formation of RNA:DNA hybrids. These structural intermediates precipitate collisions between the transcription and replication machineries. Central to mitigating this genomic threat is interleukin enhancer-binding factor 2 (ILF2), which orchestrates the recruitment of RNA:DNA helicases to resolve R-loops and, in doing so, reveals cancer cells dependency on stress-mitigating mechanisms to avert genome catastrophe. Our discovery of Molephantin and its lead derivative, NYH0002 is the outcome of delineating ILF2s function. NYH002 exerts direct binding to the ILF2 complex and disrupts RNA:DNA helicase activity to elicit genome-wide DNA breakages. Tumors with elevated cyclin E and E2F1 expression are sensitive to NYH002, while those deficient in homologous recombination repair exhibit lethality. Collectively, these findings position ILF2 as a key regulator of R-loop homeostasis and reveal a therapeutic vulnerability that NYH002 exploits to suppress tumor malignancy.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM 96%
- The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. 96%
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 96%
Similar papers in this journal
Similar papers in this journal
- SDR enzymes oxidize specific lipidic alkynylcarbinols into cytotoxic protein-reactive species 97%
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 96%
- Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger Cyclin K degradation 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.